Bespak and Aesica Announce New Business Model

Bespak and Aesica announced the launch of a new single-source supply-chain solution for drug-delivery device and pharmaceutical manufacturing services that incorporates formulation development, device design and development, drug and device manufacture, fill/finish, and secondary packaging.

The new business model follows Consort Medical’s acquisition of Aesica and aims to speed up drug development timelines while reducing cost and complexity.

Consort Medical has combined and integrated Aesica’s drug formulation, manufacturing and packaging capabilities with Bespak’s drug-delivery device design, development, and manufacturing services to create a global single source drug and device contract manufacturing partner for the pharmaceutical industry.

The services provided by the Group includes inhalation, nasal, ocular, buccal, and transdermal drug-delivery device concept generation, design, development, and manufacture at pilot through to high volume commercial scale, as well as API and formulation development and manufacture and finished dose fill and finish.

Bespak and Aesica are equipped with certified quality management systems and comply with regulatory requirements of FDA and MHRA, including cGMP and environmental and health and safety standards. Aesica provides secure facilities that handle up to schedule 2 controlled substances, together with a high containment suite capable of manufacturing products in the SafeBridge category 3 potency level.

Bespak and Aesica can provide pilot and commercial manufacturing services, including high-volume automated production operations from grams to full-scale manufacture of drugs.

Source: Bespak